- Home
- SPE vs YARW Comparison
SPE vs YARW Comparison
Compare SPE & YARW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPE | YARW |
|---|---|---|
| Founded | 1993 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.1M | 114.6M |
| IPO Year | 1994 | 2017 |
Fundamental Metrics
Financial Performance| Metric | SPE | YARW |
|---|---|---|
| Price | $13.57 | $28.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 24.7K | ★ 29.7K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | ★ 8.55% | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.02 | $28.70 |
| 52 Week High | $15.99 | $44.28 |
Technical Indicators
Market Signals| Indicator | SPE | YARW |
|---|---|---|
| Relative Strength Index (RSI) | 57.17 | 32.03 |
| Support Level | $13.51 | N/A |
| Resistance Level | $13.71 | $43.96 |
| Average True Range (ATR) | 0.15 | 3.47 |
| MACD | 0.01 | -1.45 |
| Stochastic Oscillator | 70.27 | 6.77 |
Price Performance
Historical ComparisonAbout SPE Special Opportunities Fund Inc
Special Opportunities Fund Inc is a closed-ended diversified management investment company. Its investment objective is to have the total return. The company's investment portfolio consists of investment companies, common stocks, money market funds, commodity partnerships, preferred stocks, convertible bonds, liquidating trusts, promissory notes, senior unsecured notes, warrants, rights, corporate notes and corporate bonds.
About YARW Yarrow Bioscience Inc. Common Stock
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.